裴芳, 李小鹰, 方颖. 老年原发性高血压左心室肥厚患者心肾微动脉的病理特征 [J]. {H}中华心血管病杂志, 2008, (10):872.doi: 10.3321/j.issn:0253-3758.2008.10.004.
|
惠汝太, 樊晓寒, 高莹. 高血压病的治疗进展及指南解读 [J]. {H}中国循环杂志, 2012(1):6.
|
Yamada H, Suga N, Maeda K. Effects of combination therapy with angiotensin Ⅱ type Ⅰ receptor blocker and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study [J]. {H}Arzneimittel-Forschung, 2010(2):64.
|
中国高血压防治指南修订委员会. 中国高血压防治指南2010 [J]. {H}中华心血管病杂志, 2011(7):579.doi: 10.3760/cma.j.issn.0253-3758.2011.07.002.
|
戚小惠, 乔媛秋. 高血压患者肾脏损伤指标探讨 [J]. 高血压杂志, 2006(5):396.doi: 10.3969/j.issn.1673-7245.2006.05.017.
|
王卫东. 美托洛尔联合硝苯地平缓释片治疗原发性高血压的疗效 [J]. {H}海南医学院学报, 2011(8):1046.doi: CNKI:46-1049/R.20110617.1113.014.
|
邱晓燕. 血尿酸水平与慢性充血性心衰患者心功能及高血压关系的研究 [J]. {H}海南医学院学报, 2011, (12):1633.doi: 46-1049/R.20111018.1012.011.
|
陈芳. 厄贝沙坦氢氯噻嗪片治疗老年高血压66例疗效观察 [J]. {H}实用临床医药杂志, 2013, (13):85.
|
任金娥, 蔡怡. 生活方式干预在老年高血压动脉粥样硬化患者中的应用效果 [J]. {H}实用临床医药杂志, 2013, (12):35.
|
Narumi H, Takano H, Shindo S. Effect of valsartan and arnlodipine on cardiorenal protection in Japanese hypertensive patients:the valsartan amlodipine randomized trial [J]. {H}Hypertension Research, 2011(1):62.
|
何静, 林王利, 李曙光. 缬沙坦联合左旋氨氯地平治疗原发性高血压30例 [J]. {H}医药导报, 2008, (11):1347.doi: 10.3870/j.issn.1004-0781.2008.11.023.
|
雷强, 董玉会, 严丹. 左旋氨氯地平与厄贝沙坦联合治疗糖尿病并发肾病及高血压 [J]. {H}四川医学, 2009(6):854.doi: 10.3969/j.issn.1004-0501.2009.06.029.
|
付剑云, 苏又苏, 吴京兰. 尿微量白蛋白在高血压病早期肾损伤的意义及其与低级别炎症的关系 [J]. {H}南方医科大学学报, 2007(5):699.doi: 10.3321/j.issn:1673-4254.2007.05.043.
|
Seiarretta S, Valenti V, Tocci G. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension:data from the Italy-developing education and awareness on microalbumin uria in patients with hypertensive disease study [J]. {H}Journal of Hypertension, 2010(1):251.
|
Jalal S, Sofi F A, Abass S M. Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension:a prospective study [J]. Indian J Nephrol, 2010(1):15.
|